EMA Authorised: Competact (pioglitazone;metformin hydrochloride) — CHEPLAPHARM Arzneimittel GmbH

View source ↗

Summary

The EMA authorised Competact, a fixed-dose combination of pioglitazone and metformin, for the treatment of type 2 diabetes mellitus, with CHEPLAPHARM Arzneimitt…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• Competact (pioglitazone; metformin hydrochloride)

Snippet

Status: Authorised. Therapeutic area: Diabetes Mellitus, Type 2. MAH: CHEPLAPHARM Arzneimittel GmbH. Decision date: 08/04/2025